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OBJECTIVES The goal of this study was to assess the long-term impact of creatine kinase-MB isoform
(CK-MB) elevation after percutaneous or surgical revascularization.
BACKGROUND The long-term impact of CK-MB elevation after coronary artery bypass grafting (CABG) is
not as well characterized as that following percutaneous coronary intervention (PCI).
METHODS The three-year cumulative survival of consecutive patients who underwent their first
percutaneous or surgical revascularization procedure between January 1, 1995 and August 31,
2000 and had CK-MB determination was assessed using the Social Security Death Index.
RESULTS The 3,812 patients undergoing CABG had a less favorable coronary risk profile than the
3,573 patients undergoing PCI. The incidence of CK-MB elevation above normal range was
90% and 38% for the CABG and PCI groups (p  0.001). In 6% and 5%, respectively, the
elevation surpassed 10 the upper limit of normal (ULN). At an average follow-up of three
years, there were 712 deaths, 83 of which occurred within 30 days of procedure. The
cumulative survival was 92% and 90% for CABG and PCI, respectively (p 0.003). Chronic
renal insufficiency (adjusted hazard ratio [HR] 3.8, [95% confidence interval 3.1 to 4.6]), age
(HR 1.5 per decade [1.3 to 1.6]), ejection fraction 40% (HR 1.3 [1.1 to 1.5] and PCI (HR
1.6 [1.3 to 1.9]) were the main predictors of increased mortality. Creatine kinase-MB isoform
elevation only above 10 ULN was independently predictive of mortality in the CABG (HR
1.3 [1.1 to 1.5]) and PCI (HR 1.1 [1.0 to 1.2]) groups, p  0.001.
CONCLUSIONS Creatine kinase MB isoform elevation after revascularization is very common, particularly in
CABG patients. When extensive, it is independently correlated with increased mortality over
a three-year period. Identification and aggressive management of patients with high levels of
CK-MB after revascularization may improve their outcome. (J Am Coll Cardiol 2002;40:
1961–7) © 2002 by the American College of Cardiology Foundation
Routine surveillance of creatine kinase-MB isoform (CK-
MB) after percutaneous coronary intervention (PCI) dem-
onstrates periprocedural elevation in 10% to 40% of pa-
tients, which is almost always not associated with immediate
clinical manifestations. Numerous series have described an
adverse long-term effect of this apparently innocuous man-
ifestation of transient vessel closure, profound ischemia, and
distal embolization without clearly establishing a causative
relationship (1,2). This association has been less well estab-
lished after coronary artery bypass grafting (CABG). It was
generally assumed that CK-MB elevation after cardiac
manipulation is expected and, thus, a clear threshold above
which elevation in cardiac markers is indicative of signifi-
cant damage has not been accepted (3,4).
Thus, we sought to address two issues. The first objective
was to identify the frequency and magnitude of CK-MB
fraction elevation in a large cohort of patients undergoing
surgical or percutaneous revascularization, taking advantage
of the routine measurement of this parameter at our
institution. The second aim was to correlate these findings
with long-term mortality and evaluate the potential effect of
various parameters prospectively collected on this associa-
tion, in the context of the inherent selection process of
referral for either type of revascularization.
METHODS
Between January 1, 1995 and August 31, 2000, consecutive
patients surviving for at least 24 h of their first percutaneous
or surgical revascularization procedure at our institution
were considered for analysis if they had CK-MB measure-
ment and a valid social security number. We excluded
patients who had a myocardial infarction (MI) within 24 h
before revascularization, or who had emergency CABG
after PCI. The two registries collecting data for the CABG
and PCI patients were queried, and an integrated data set
was created including similar variables. Patients with repeat
procedures were counted only once and indexed according
to initial revascularization. The achievement of complete
revascularization for each patient was determined by oper-
ator according to extent of coronary disease and number of
revascularized arteries in separate coronary territories. Cre-
atine kinase-MB isoform was measured routinely 8 and 16 h
after PCI, and immediately after and the next morning for
CABG. Additional measurements were done for clinical
indications. Creatine kinase-MB isoform level was de-
scribed both as a continuous and as a discrete variable in the
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following categories of multiples of upper limit of normal
for the institution ([ULN] 8.8 ng/ml): 1, 1 to 3, 3 to 5, 5
to 10, and 10  ULN.
Survival was assessed using the Social Security Death
Index (SSDI). Duration of follow-up was determined from
date of procedure to death or date of SSDI query.
Continuous variables were compared with analysis of
variance, and discrete variables were analyzed with chi-
square test. Kaplan-Meier survival analysis was used for
cumulative survival, and Cox proportional hazards model
was used to determine independent predictors of outcomes,
using the STATISTICA 5.1 software (StatSoft Inc., 1998,
Tulsa, Oklahoma). Family history of coronary artery disease
(CAD) before age 55 was populated in less than 75% of
cases, while the incidence of hyperlipidemia and current
smoking was not reliably recorded; these variables were not
entered in multivariate models.
RESULTS
We identified 7,385 patients eligible for this analysis, 3,812
in the CABG and 3,573 in the PCI cohorts, among 17,567
total procedures. Main reasons for exclusion were for lack of
CK-MB measurement (41%) or repeat procedures (34%).
Their baseline characteristics are shown in Table 1. Most of
the variables indicated a higher risk profile in the CABG
group with the expected exception of prior CABG.
The procedural details are shown in Table 2. There was
significantly more complete revascularization in the CABG
group in conjunction with a greater extent of coronary artery
disease (CAD), more than a quarter of whom (n  1,002)
had 50% left main coronary stenosis.
The average follow-up was approximately three years
(1,159  480 days) for the whole cohort (1,276  411 vs.
1,035  516 for CABG and PCI, respectively, p  0.01),
and 712 patients died. Among the 362 deaths in the CABG
group, the average interval from procedure to death was 648
 508 days (median 632 days). In the PCI group, the
interval between procedure and death in 350 patients was
552  513 days (median 387 days). In 83 patients (12% of
all fatalities, 39 patients in the CABG and 44 patients in the
PCI groups), death occurred between two and 30 days from
procedure. The majority of the deaths occurred, thus, at
substantial intervals from the procedure. There was no
correlation between the time to death and level of CK-MB
elevation. The interval to death in patients with 10 
ULN CK-MB elevation was lower than that in the other
levels both for CABG (528  480 days) and PCI (483 
558 days). Nevertheless, even in this group most deaths
occurred one to two years after the procedure.
CK-MB elevation and cumulative rates of survival. The
cumulative survival rate in patients according to revascular-
ization strategy is shown in Figure 1. In the whole cohort,
compared with PCI, CABG was associated with improved
survival (three-year rate of 92% vs. 90%, p  0.003). In
patients with 10  ULN CK-MB elevation, the three-
year survival was not statistically different between the
revascularization strategies (p  0.99, Fig. 2). In this group,
the mean CK-MB level was identical in the two revascu-
larization groups (p  0.99). The cumulative three-year
death rates according to level of CK-MB elevation and
revascularization strategy are shown in Table 3.
Multivariate regression analysis. As the two cohorts of
patients were different in many important aspects, Cox
proportional hazards model analysis was performed. The
model included: age (continuous), gender, hypertension,
diabetes, hyperlipidemia, chronic renal insufficiency, prior
MI, prior CABG, ejection fraction 40%, number of
diseased vessels, revascularization procedure, CK-MB (con-
tinuous or ordinate), and completeness of revascularization.
Abbreviations and Acronyms
ARTS  Arterial Revascularization Therapy Study
CABG  coronary artery bypass grafting
CAD  coronary artery disease
CI  confidence interval
CK-MB  creatine kinase-MB isoform
HR  hazard ratio
MI  myocardial infarction
PCI  percutaneous coronary intervention
SSDI  Social Security Death Index
ULN  upper limit of normal
Table 1. Baseline Characteristics of the Study Population
Parameters
CABG
(n  3,812)
PCI
(n  3,573) p Value
Age, yrs 65  10 64  11 0.14
Female gender, n (%) 981 (26) 1,016 (29) 0.007
Hypertension, n (%) 2,839 (77) 2,436 (68)  0.001
Diabetes, n (%) 1,288 (37) 1,015 (28)  0.001
Premature CAD*, n (%) 827 (48) 1,496 (42)  0.001
CRF, n (%) 207 (5) 147 (4) 0.008
Prior MI, n (%) 2,354 (62) 1,519 (44)  0.001
Prior CABG, n (%) 787 (21) 1,054 (30)  0.001
Data presented as % of patients with available information. *Refers to MI before age
55 in first degree relative, data available in 5,286 patients.
CABG  coronary artery bypass grafting; CAD  coronary artery disease;
CRF  chronic renal insufficiency (serum creatinine  1.5 mg/dl); MI  myocardial
infarction; PCI  percutaneous coronary intervention.
Table 2. Angiographic and Procedural Details in the Study
Population
Parameters
CABG
(n  3,812)
PCI
(n  3,573) p Value
LVEF  40%, n (%) 854 (22) 674 (20) 0.009
Extent of CAD, n 2.7  0.6 1.9  0.9  0.001
Complete revasc., n (%) 2,295 (78) 2,251 (64)  0.001
Mean peak CK-MB, ng/ml 34  46 20  44  0.001
Median peak CK-MB (IQR) 22 (14–36) 5 (2.3–16)
CK-MB  1  ULN, n (%) 3,426 (90) 1,375 (38)  0.001
CK-MB  3  ULN, n (%) 1,504 (39) 591 (17)  0.001
CK-MB  5  ULN, n (%) 615 (17) 384 (11)  0.001
CK-MB  10  ULN, n (%) 224 (6) 189 (5) 0.27
CABG  coronary artery bypass grafting; CAD  coronary artery disease; CK 
creatine kinase; IQR interquartile range; LVEF left ventricular ejection fraction;
PCI  percutaneous coronary intervention; ULN  upper limit of normal.
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For the whole population, the most significant predictors of
increased mortality (at p  0.001), in order of contribution
to the overall model, were chronic renal insufficiency (haz-
ard ratio [HR] 3.8 [95% confidence interval {CI} 3.1 to
4.6]), age (HR 1.5 per decade [1.3 to 1.6]), ejection fraction
40% (HR 1.3 [1.1 to 1.5], and PCI (HR 1.6 [1.3 to 1.9]).
Extent of CAD, diabetes mellitus, prior MI, female gender,
and absence of complete revascularization were weaker
predictors. When examined as a continuous variable,
CK-MB elevation is significantly associated with increased
mortality, but Figures 3 and 4 clearly show the lack of a
consistent relationship between this parameter and mortal-
ity. Thus, we analyzed for each revascularization strategy the
independent contribution to mortality of each level of
CK-MB elevation, compared with no CK-MB elevation,
using the same regression model described above. Only in
the patients with the highest level of CK-MB elevation
(10  ULN) was there a significant independent contri-
Figure 1. Cumulative survival in coronary artery bypass grafting (dashed line) and percutaneous coronary intervention (solid line) patients.
Figure 2. Cumulative survival in coronary artery bypass grafting (dashed line) and percutaneous coronary intervention (solid line) patients with creatine
kinase-MB isoform elevation 10  the upper limit of normal.
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bution to mortality (HR 1.3 [1.1 to 1.5], p  0.01 for
CABG and HR 1.1 [1.0 to 1.2], p  0.01 for PCI).
DISCUSSION
This is the largest and most comprehensive analysis of the
association between long-term survival and periprocedural
CK-MB elevation after percutaneous or surgical revascular-
ization in unselected patients at a tertiary institution. Unlike
in clinical trials comparing the two revascularization tech-
niques (5–11), the patients differ substantially with respect
to clinical and angiographic characteristics. The key obser-
vations from this study are that 38% of PCI and 90% of
CABG patients have some degree of CK-MB elevation
after revascularization. In 16% of PCI and 17% of CABG
patients, the CK-MB elevation surpassed the threshold
utilized for MI adjudication in clinical trials, 3  ULN
and 5  ULN, respectively. Our analysis demonstrates
that these thresholds overestimate the actual independent
contribution of CK-MB elevation to mortality, as patients
with CK-MB elevation of 7  ULN and 15  ULN, for
example, would be included in the 5  ULN group,
despite different impact on outcome after multivariable
adjustment.
The PCI patients demonstrate a more consistent link
between CK-MB elevation and mortality, while in the
CABG group this association more resembles a threshold
phenomenon surrounding the 10  ULN value. The
mechanism of CK-MB elevation after revascularization may
partially explain the difference in impact on outcome.
During PCI, it is mostly related to distal embolization of
plaque material and usually not associated with procedural
failure (12). In contrast, CABG patients with high levels of
CK-MB are likely to be affected by early graft failure and/or
lack of adequate myocardial protection during bypass (13–
16). Furthermore, as CABG patients have more severe
native coronary disease (including left main coronary steno-
sis), the territory jeopardized by graft failure is large. In
addition, it is possible that distal embolization plays an
important role in CABG patients as well, particularly
during anastomosis of grafts in severely diseased native
Table 3. Population At Risk and Cumulative Three-Year
Mortality Rates Associated With Ascending Levels of CK-MB
Elevation
CK-MB
CABG (n  3,812) PCI (n  3,573)
n At Risk,
(%)
Death,
(%)
n At Risk,
(%)
Death,
(%)
1  ULN 386 (10) 7.2 2,198 (62) 7.0
1–3  ULN 1,922 (50) 7.7 784 (22) 11.7
3–5  ULN 853 (22) 6.3 207 (6) 14.7
5–10  ULN 427 (11) 7.5 195 (5) 14.5
10  ULN 224 (6) 20.8 189 (5) 17.7
p (trend)  0.001  0.001
CABG  coronary artery bypass grafting; CK-MB  creatine kinase-MB isoform;
PCI  percutaneous coronary intervention; ULN  upper limit of normal.
Figure 3. Cumulative survival in coronary artery bypass grafting patients according to level of creatine kinase-MB isoform elevation. ULN  upper limit
of normal.
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arteries. These patients may benefit from early repeat
angiography to identify and reverse graft failure, despite the
occurrence of myocardia damage (17–19).
In a recent series of 2,003 CABG patients, 3.5% were
found to have CK-MB 80 U/l (equivalent to approxi-
mately 10  ULN in our study). A total of 90% of these
patients had documented graft failure, which resulted in
considerable mortality (20). Fitzgibbon et al. (21) reported
on 1,388 patients with first CABG who underwent system-
atic angiography. Among the vein grafts, 12% exhibited
early closure.
Is CK-MB elevation synonymous with myonecrosis?
Recently, magnetic resonance scans of patients with peri-
PCI CK-MB elevation (median 21 ng/ml) demonstrated
discrete areas of hyperenhancement (necrosis) in the PCI
territory, which did not occur in patients without CK-MB
elevation (22). Likely, this observation would apply to
CABG patients as well.
Comparison with previous studies. Only two studies ad-
dressed the long-term impact of CK-MB elevation after
CABG. In the Arterial Revascularization Therapy Study
(ARTS), CK-MB was systemically measured after the
procedure in 496 patients. The incidence of any CK-MB
elevation was 62%, and the mortality at one year in patients
with CK-MB 5  ULN was 7%, as compared with 6% in
our study (23,24). Similarly, in the GUARD during Isch-
emia Against Necrosis (GUARDIAN) study, patients at
high-risk for CABG complications had a six-month mor-
tality of 3.4%, 5.8%, 7.8%, and 20.2% for CK-MB levels of
1 , 5 , 10 , and 20  ULN, respectively, p 
0.0001 (25). The relationship remained statistically signifi-
cant after adjustment for ejection fraction, congestive heart
failure, cerebrovascular disease, peripheral vascular disease,
cardiac arrhythmia, and the method of cardioplegia delivery
and demonstrated the best cut-off point for mortality
prediction in the 5 to 10  ULN range. Most of the other
series correlated techniques of myocardial protection with
incidence of myonecrosis and short-term operative compli-
cations (26–28).
Numerous series have evaluated the impact of peri-PCI
CK-MB elevation on medium- and long-term survival, as
summarized by Califf et al. (1). The incidence of CK-MB
elevation in these series is comparable to the one in our
report. Abdelmeguid and Topol (29,30) pointed out that
even small CK-MB elevations after PCI are associated with
increases in mortality over 8.5 years. Kong et al. (31)
reported similar data. In randomized clinical trials, CK-MB
elevation in the context of PCI with abciximab was associ-
ated with 50% to 140% excess mortality over three years,
across the range of CK-MB elevation used in the current
report (2). Other series from trials of coronary stenting
reported an increase in mortality of up to fourfold in
patients with large periprocedural enzyme elevation (32–
34).
Also of interest is the fact that high-risk characteristics in
the population described in this study resulted in worse
Figure 4. Cumulative survival in percutaneous coronary intervention patients according to level of creatine kinase-MB isoform elevation. ULN  upper
limit of normal.
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survival than in patients enrolled in clinical trials comparing
the two strategies of revascularization. For example, in the
Bypass Angioplasty Revascularization Investigation (BARI)
trial, the three-year mortality among 1,829 patients ran-
domized to CABG or PCI was approximately 5% and 6%,
respectively (7), as compared with 8% and 10%, respectively,
in this report. In the Emory Angioplasty versus Surgery
Trial (EAST), at three years the mortality was 6% and 7%
in the two groups, respectively (8). In the Randomized
Intervention Treatment of Angina (RITA-1) trial, the
mortality at 2.5 years was only 3.6% and 3.1%, respectively
(10). In a Veterans’ Administration study dedicated to
patients at high-risk, mortality at three years was 21% and
20%, respectively (35). Contemporary studies of CABG
versus PCI, such as ARTS, feature a mortality rate of only
4% to 5% at three years (5), highlighting the major
difference between randomized clinical trials in which pa-
tients are eligible and suitable for both procedures and
clinical practice, where appropriate triage to one revascular-
ization strategy is based on a multitude of clinical and
angiographic parameters, integrated with evidence from
clinical trials.
Study limitations. As in any retrospective analysis, impor-
tant limitations preclude definitive conclusions. We recog-
nize that while peak CK-MB correlates in general with
infarct size, this association is far from perfect and may be
affected by the mechanism of infarction in the two groups.
Moreover, the adherence to guidelines of CK-MB collec-
tion could not be verified, allowing for the possibility that
the actual peak value was missed and leading to exclusion of
many patients. We do not have information on the cause of
death and, thus, may overstate the contribution of coronary
disease and revascularization to outcome. We also did not
have information on previous or subsequent medical man-
agement and revascularization, which may have affected the
relation between CK-MB elevation and survival.
Conclusions. Despite these limitations, we conclude that
CK-MB elevation is extremely common after revasculariza-
tion, particularly with surgery. The three-year survival is
independently affected by the degree of CK-MB elevation
and is particularly impaired in patients exhibiting extensive
CK-MB elevation. Nevertheless, other clinical parameters
are much stronger predictors of mortality than CK-MB
elevation. Routine measurement of CK-MB after revascu-
larization is critical in identifying patients at high risk for
subsequent death.
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